The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 29, 2020

Filed:

Nov. 06, 2017
Applicants:

Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);

Yale University, New Haven, CT (US);

Institute for Research IN Biomedicine (Irb), Bellinzona, CH;

Inventors:

Richard Flavell, Guilford, CT (US);

Till Strowig, Braunschweig, DE;

Markus G. Manz, Zollikon, CH;

Chiara Borsotti, Bronxville, NY (US);

Madhav Dhodapkar, New Haven, CT (US);

Andrew J. Murphy, Croton-on-Hudson, NY (US);

Sean Stevens, San Diego, CA (US);

George D. Yancopoulos, Yorktown Heights, NY (US);

Assignees:

Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);

Yale University, New Haven, CT (US);

Institute for Research in Biomedicine (IRB), Bellinzona, CH;

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A01K 67/027 (2006.01); C07K 14/535 (2006.01); C07K 14/54 (2006.01); C07K 14/52 (2006.01); A61K 49/00 (2006.01);
U.S. Cl.
CPC ...
A01K 67/0278 (2013.01); A01K 67/0276 (2013.01); A01K 2207/15 (2013.01); A01K 2217/052 (2013.01); A01K 2217/072 (2013.01); A01K 2217/075 (2013.01); A01K 2217/15 (2013.01); A01K 2227/105 (2013.01); A01K 2267/01 (2013.01); A61K 49/0008 (2013.01); C07K 14/524 (2013.01); C07K 14/535 (2013.01); C07K 14/5403 (2013.01); C07K 14/5412 (2013.01);
Abstract

Genetically modified non-human animals are provided that may be used to model human hematopoietic cell development, function, or disease. The genetically modified non-human animals comprise a nucleic acid encoding human IL-6 operably linked to an IL-6 promoter. In some instances, the genetically modified non-human animal expressing human IL-6 also expresses at least one of human M-CSF, human IL-3, human GM-CSF, human SIRPa or human TPO. In some instances, the genetically modified non-human animal is immunodeficient. In some such instances, the genetically modified non-human animal is engrafted with healthy or diseased human hematopoietic cells. Also provided are methods for using the subject genetically modified non-human animals in modeling human hematopoietic cell development, function, and/or disease, as well as reagents and kits thereof that find use in making the subject genetically modified non-human animals and/or practicing the subject methods.


Find Patent Forward Citations

Loading…